The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Medimmune competitive analysis

Loading summary...

Latest patents of Medimmune opposed by its competitors

Explore Medimmune's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3218406
Oct 2, 2024Binding Molecules Specific For Cd73 And Uses Thereof2
EP3157629
Oct 5, 2022Methods Of Cancer Treatment With Antagonists Against Pd-1 And Pd-L1 In Combination With Radiation Therapy1
EP1942939
Jul 7, 2021Interleukin-13 Antibody Composition1
EP3329018
Mar 31, 2021Methods For Treating Hepcidin-Mediated Disorders1
EP2997036
Mar 3, 2021Purification Of Recombinantly Produced Polypeptides2
EP2935268
Feb 17, 2021Pyrrolobenzodiazepines And Conjugates Thereof1
EP2624859
Mar 1, 2017Factor Ii And Fibrinogen For Treatment Of Haemostatic Disorders1

Latest PTAB cases involving Medimmune

Discover the latest PTAB cases involving Medimmune, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Medimmune with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
MEDIMMUNE - 9 - -
GLAXOSMITHKLINE29112812
JAMES POOLE153 - - -
STRAWMAN339 - - -